Reducing brain kynurenic acid synthesis precludes kynurenine-induced sleep disturbances

Patients with neurocognitive disorders often battle sleep disturbances. Kynurenic acid is a tryptophan metabolite of the kynurenine pathway implicated in the pathology of these illnesses. Modest increases in kynurenic acid, an antagonist at glutamatergic and cholinergic receptors, result in cognitive impairments and sleep dysfunction. We explored the hypothesis that inhibition of the kynurenic acid synthesising enzyme, kynurenine aminotransferase II, may alleviate sleep disturbances. At the start of the light phase, adult male and female Wistar rats received systemic injections of either: (i) vehicle; (ii) kynurenine (100 mg kg-1; i.p.); (iii) the kynurenine aminotransferase II inhibitor, PF-04859989 (30 mg kg-1; s.c.); or (iv) PF-04859989 and kynurenine in combination. Kynurenine and kynurenic acid levels were evaluated in the plasma and brain. Separate animals were implanted with electroencephalogram and electromyogram telemetry devices to record polysomnography, and evaluate the vigilance states wake, rapid eye movement sleep and non-rapid eye movement sleep following each treatment. Kynurenine challenge increased brain kynurenic acid and resulted in reduced rapid eye movement sleep duration, non-rapid eye movement sleep delta power and sleep spindles. PF-04859989 reduced brain kynurenic acid formation when given prior to kynurenine, prevented disturbances in rapid eye movement sleep and sleep spindles, and enhanced non-rapid eye movement sleep. Our findings suggest that reducing kynurenic acid in conditions where the kynurenine pathway is activated may serve as a potential strategy for improving sleep dynamics.

The Sleep Quality- and Myopia-Linked PDE11A-Y727C Variant Impacts Neural Physiology by Reducing Catalytic Activity and Altering Subcellular Compartmentalization of the Enzyme

Recently, a Y727C variant in the dual-specific 3',5'-cyclic nucleotide phosphodiesterase 11A (PDE11A-Y727C) was linked to increased sleep quality and reduced myopia risk in humans. Given the well-established role that the PDE11 substrates cAMP and cGMP play in eye physiology and sleep, we determined if (1) PDE11A protein is expressed in the retina or other eye segments in mice, (2) PDE11A-Y7272C affects catalytic activity and/or subcellular compartmentalization more so than the nearby suicide-associated PDE11A-M878V variant, and (3) Pde11a deletion alters eye growth or sleep quality in male and female mice. Western blots show distinct protein expression of PDE11A4, but not PDE11A1-3, in eyes of Pde11a WT, but not KO mice, that vary by eye segment and age. In HT22 and COS-1 cells, PDE11A4-Y727C reduces PDE11A4 catalytic activity far more than PDE11A4-M878V, with both variants reducing PDE11A4-cAMP more so than PDE11A4-cGMP activity. Despite this, Pde11a deletion does not alter age-related changes in retinal or lens thickness or axial length, nor vitreous or anterior chamber depth. Further, Pde11a deletion only minimally changes refractive error and sleep quality. That said, both variants also dramatically alter the subcellular compartmentalization of human and mouse PDE11A4, an effect occurring independently of dephosphorylating PDE11A4-S117/S124 or phosphorylating PDE11A4-S162. Rather, re-compartmentalization of PDE11A4-Y727C is due to the loss of the tyrosine changing how PDE11A4 is packaged/repackaged via the trans-Golgi network. Therefore, the protective impact of the Y727C variant may reflect a gain-of-function (e.g., PDE11A4 displacing another PDE) that warrants further investigation in the context of reversing/preventing sleep disturbances or myopia.

The sleep quality- and myopia-linked PDE11A-Y727C variant impacts neural physiology by reducing catalytic activity and altering subcellular compartmentalization of the enzyme

Recently, a Y727C variant in the dual-specific 3',5'-cyclic nucleotide phosphodiesterase 11A (PDE11A-Y727C) was linked to increased sleep quality and reduced myopia risk in humans. Given the well-established role that the PDE11 substrates cAMP and cGMP play in eye physiology and sleep, we determined if 1) PDE11A protein is expressed in the retina or other eye segments in mouse, 2) PDE11A-Y7272C affects catalytic activity and/or subcellular compartmentalization more so than the nearby suicide-associated PDE11A-M878V variant, and 3) Pde11a deletion alters eye growth or sleep quality in male and female mice. Western blots show distinct protein expression of PDE11A4, but not PDE11A1-3, in eyes of Pde11a WT-but not KO mice-that vary by eye segment and age. In HT22 and COS-1 cells, PDE11A4-Y727C reduces PDE11A4 catalytic activity far more than PDE11A4-M878V, with both variants reducing PDE11A4-cAMP more so than PDE11A4-cGMP activity. Despite this, Pde11a deletion does not alter age-related changes in retinal or lens thickness, axial length, nor vitreous or anterior chamber depth. Further, Pde11a deletion only minimally changes refractive error and sleep quality. That said, both variants also dramatically alter the subcellular compartmentalization of human and mouse PDE11A4, an effect occurring independently of dephosphorylating PDE11A4-S117/S124 or phosphorylating PDE11A4-S162. Rather, re-compartmentalization of PDE11A4-Y727C is due to the loss of the tyrosine changing how PDE11A4 is packaged/repackaged via the trans-Golgi network. Therefore, the protective impact of the Y727C variant may reflect a gain-of-function (e.g., PDE11A4 displacing another PDE) that warrants further investigation in the context of reversing/preventing sleep disturbances or myopia.

The stress of losing sleep: Sex-specific neurobiological outcomes

Sleep is a vital and evolutionarily conserved process, critical to daily functioning and homeostatic balance. Losing sleep is inherently stressful and leads to numerous detrimental physiological outcomes. Despite sleep disturbances affecting everyone, women and female rodents are often excluded or underrepresented in clinical and pre-clinical studies. Advancing our understanding of the role of biological sex in the responses to sleep loss stands to greatly improve our ability to understand and treat health consequences of insufficient sleep. As such, this review discusses sex differences in response to sleep deprivation, with a focus on the sympathetic nervous system stress response and activation of the hypothalamic-pituitary-adrenal (HPA) axis. We review sex differences in several stress-related consequences of sleep loss, including inflammation, learning and memory deficits, and mood related changes. Focusing on women's health, we discuss the effects of sleep deprivation during the peripartum period. In closing, we present neurobiological mechanisms, including the contribution of sex hormones, orexins, circadian timing systems, and astrocytic neuromodulation, that may underlie potential sex differences in sleep deprivation responses.

Kynurenine aminotransferase II inhibition promotes sleep and rescues impairments induced by neurodevelopmental insult

Dysregulated sleep is commonly reported in individuals with neuropsychiatric disorders, including schizophrenia (SCZ) and bipolar disorder (BPD). Physiology and pathogenesis of these disorders points to aberrant metabolism, during neurodevelopment and adulthood, of tryptophan via the kynurenine pathway (KP). Kynurenic acid (KYNA), a neuroactive KP metabolite derived from its precursor kynurenine by kynurenine aminotransferase II (KAT II), is increased in the brains of individuals with SCZ and BPD. We hypothesize that elevated KYNA, an inhibitor of glutamatergic and cholinergic neurotransmission, contributes to sleep dysfunction. Employing the embryonic kynurenine (EKyn) paradigm to elevate fetal brain KYNA, we presently examined pharmacological inhibition of KAT II to reduce KYNA in adulthood to improve sleep quality. Pregnant Wistar rats were fed either kynurenine (100 mg/day)(EKyn) or control (ECon) diet from embryonic day (ED) 15 to ED 22. Adult male (N = 24) and female (N = 23) offspring were implanted with devices to record electroencephalogram (EEG) and electromyogram (EMG) telemetrically for sleep-wake data acquisition. Each subject was treated with either vehicle or PF-04859989 (30 mg/kg, s.c.), an irreversible KAT II inhibitor, at zeitgeber time (ZT) 0 or ZT 12. KAT II inhibitor improved sleep architecture maintaining entrainment of the light-dark cycle; ZT 0 treatment with PF-04859989 induced transient improvements in rapid eye movement (REM) and non-REM (NREM) sleep during the immediate light phase, while the impact of ZT 12 treatment was delayed until the subsequent light phase. PF-04859989 administration at ZT 0 enhanced NREM delta spectral power and reduced activity and body temperature. In conclusion, reducing de novo KYNA production alleviated sleep disturbances and increased sleep quality in EKyn, while also improving sleep outcomes in ECon offspring. Our findings place attention on KAT II inhibition as a novel mechanistic approach to treating disrupted sleep behavior with potential translational implications for patients with neurodevelopmental and neuropsychiatric disorders.

0173 Kynurenine aminotransferase II inhibition improves sleep architecture in adult male and female rats exposed to kynurenic acid elevation during development

Introduction

Dysregulated sleep and cognitive impairments are commonly reported in individuals with psychotic disorders, including schizophrenia (SZ) and bipolar disorder (BPD). Emerging evidence implicates the kynurenine pathway (KP) of tryptophan catabolism in the pathophysiology of psychotic disorders. Kynurenic acid (KYNA), a KP metabolite synthetized by kynurenine aminotransferases (KATs) from its biological precursor kynurenine, is elevated in brain tissue and the cerebrospinal fluid of patients with SZ and BPD. KYNA is hypothesized to play a key role in sleep disturbances, thus, we presently investigate if pharmacological inhibition of KAT II to reduce brain KYNA formation may overcome sleep.

Methods

We employed the embryonic kynurenine (EKyn) paradigm to induce KYNA elevation in the fetal brain (Pocivavsek et al 2014 Psychopharm). Wistar dams were fed either kynurenine (100 mg/day) (EKyn) or control wet mash (ECon) from embryonic day (ED) 15 to ED 22. Adult (postnatal day 56-85) male and female offspring were used in sleep studies (EEG/EMG telemetry) to evaluate the effectiveness of PF-04859989 (30 mg/kg, s.c.), an irreversible KAT II inhibitor. Each subject was treated at zeitgeber time (ZT) 0 with either vehicle or PF-04859989 and rapid-eye movement (REM) sleep, non-REM (NREM) sleep, and wakefulness parameters were assessed.

Results

KAT II inhibition significantly increased REM duration during the second half of the light phase in both male (P<0.01) and female (P<0.05) EKyn compared to vehicle treatment. PF-04859989 increased NREM duration and reduced wakefulness during the latter part of the dark phase in both ECon and EKyn male rats, accompanied with significant decrease in relative cage activity, but no differences were determined in female rats across 24 hr. Light phase analysis of spectral power during NREM sleep in EKyn rats revealed significant frequency by treatment interaction (P<0.0001) in males only, with enhanced delta power (0-4 Hz) after PF-04859989 treatment.

Conclusion

Acute decrease in brain KYNA mitigates sleep deficits and elicits higher quality sleep in male EKyn offspring, suggesting KAT II inhibition as a novel mechanistic approach to treating sleep deficiencies in a translationally-relevant preclinical paradigm.

Support (If Any)

This work was funded by National Institutes of Health Grant Nos. NIH R01 NS102209 & P50 MH103222.

0298 Kynurenic Acid Synthesis Inhibitor Promotes Enhanced Sleep Recovery Following Acute Sleep Deprivation in Adult Wistar Rats

Introduction

Sleep disorders and cognitive dysfunction often afflict the general population and are common amongst patients with neuropsychiatric disorders like schizophrenia. Sleep deprivation (SD) disrupts cognitive function, yet little is known about underlying mechanisms. The tryptophan metabolite kynurenic acid (KYNA), an endogenous a7nACh and NMDA receptor antagonist, is synthesized by kynurenine aminotransferase II (KAT II). KYNA is increased in the brain of patients with schizophrenia and our translational studies demonstrate that elevated KYNA disrupts hippocampal learning and sleep architecture in rodents (Pocivavsek et al. 2017 Sleep). We hypothesize a mechanistic link between KYNA, sleep, and cognitive dysfunction.

Methods

In vivo microdialysis in the dorsal hippocampus and simultaneous EEG/EMG telemetry was conducted in adult male Wistar rats (N=3-5 per group). Using a within-subjects experimental design, rats underwent a control and SD day. Animals received either vehicle or KAT II inhibitor PF-04859989 (PF), 30mg/kg s.c., on both days at zeitgeber time (ZT) 0 or ZT6. SD occurred from ZT0-6 by gentle handling. KYNA levels were evaluated in the microdialysate.

Results

SD effectively eliminated REM sleep (100%) and significantly reduced NREM (94%) during ZT0-6. Extracellular KYNA levels in the hippocampus significantly increased with SD (2-way ANOVA, time x SD: **P<0.0001) and PF readily prevented this accumulation. Initial sleep recovery (ZT6-12) did not significantly differ between treatment groups. During the dark phase (ZT12-24), PF treatment of SD animals promoted REM sleep parameters, including total REM duration (2-way ANOVA, SD x treatment ZT: P<0.05). PF treatment enhanced theta spectral power determined by Discrete Fourier transform during REM sleep recovery (ZT12-24). PF alone during the control day enhanced NREM delta power (P<0.05) during the late light phase (ZT6-12).

Conclusion

Importantly, the KAT II inhibitor PF promoted sleep recovery following acute SD, supporting our hypothesis that the accumulation of KYNA may exacerbate sleep disruptions. Changes in sleep parameters elicited by PF, a potential therapeutic avenue, may be indicative of mild somnolence. The present and future complementary experiments with cognitive behavioral tasks in rodents support our understanding of the role of KYNA in modulating sleep and cognition.

Support (If Any)

National Institutes of Health Grant No. NIH R01 NS102209

Application of Machine Learning to Sleep Stage Classification

Sleep studies are imperative to recapitulate phenotypes associated with sleep loss and uncover mechanisms contributing to psychopathology. Most often, investigators manually classify the polysomnography into vigilance states, which is time-consuming, requires extensive training, and is prone to inter-scorer variability. While many works have successfully developed automated vigilance state classifiers based on multiple EEG channels, we aim to produce an automated and openaccess classifier that can reliably predict vigilance state based on a single cortical electroencephalogram (EEG) from rodents to minimize the disadvantages that accompany tethering small animals via wires to computer programs. Approximately 427 hours of continuously monitored EEG, electromyogram (EMG), and activity were labeled by a domain expert out of 571 hours of total data. Here we evaluate the performance of various machine learning techniques on classifying 10-second epochs into one of three discrete classes: paradoxical, slow-wave, or wake. Our investigations include Decision Trees, Random Forests, Naive Bayes Classifiers, Logistic Regression Classifiers, and Artificial Neural Networks. These methodologies have achieved accuracies ranging from approximately 74% to approximately 96%. Most notably, the Random Forest and the ANN achieved remarkable accuracies of 95.78% and 93.31%, respectively. Here we have shown the potential of various machine learning classifiers to automatically, accurately, and reliably classify vigilance states based on a single EEG reading and a single EMG reading.

Prenatal Kynurenine Elevation Elicits Sex-Dependent Changes in Sleep and Arousal During Adulthood: Implications for Psychotic Disorders

Dysregulation of the kynurenine pathway (KP) of tryptophan catabolism has been implicated in psychotic disorders, including schizophrenia and bipolar disorder. Kynurenic acid (KYNA) is a KP metabolite synthesized by kynurenine aminotransferases (KATs) from its biological precursor kynurenine and acts as an endogenous antagonist of N-methyl-D-aspartate and α7-nicotinic acetylcholine receptors. Elevated KYNA levels found in postmortem brain tissue and cerebrospinal fluid of patients are hypothesized to play a key role in the etiology of cognitive symptoms observed in psychotic disorders. Sleep plays an important role in memory consolidation, and sleep disturbances are common among patients. Yet, little is known about the effect of altered KP metabolism on sleep-wake behavior. We presently utilized a well-established experimental paradigm of embryonic kynurenine (EKyn) exposure wherein pregnant dams are fed a diet laced with kynurenine the last week of gestation and hypothesized disrupted sleep-wake behavior in adult offspring. We examined sleep behavior in adult male and female offspring using electroencephalogram and electromyogram telemetry and determined sex differences in sleep and arousal in EKyn offspring. EKyn males displayed reduced rapid eye movement sleep, while female EKyn offspring were hyperaroused compared to controls. We determined that EKyn males maintain elevated brain KYNA levels, while KYNA levels were unchanged in EKyn females, yet the activity levels of KAT I and KAT II were reduced. Our findings indicate that elevated prenatal kynurenine exposure elicits sex-specific changes in sleep-wake behavior, arousal, and KP metabolism.

Methylation-dependent regulation of hypoxia inducible factor-1 alpha gene expression by the transcription factor Kaiso

Low oxygen tension (hypoxia) is a common characteristic of solid tumors and strongly correlates with poor prognosis and resistance to treatment. In response to hypoxia, cells initiate a cascade of transcriptional events regulated by the hypoxia inducible factor-1 (HIF-1) heterodimer. Since the oxygen-sensitive HIF-1α subunit is stabilized during hypoxia, it functions as the regulatory subunit of the protein. To date, while the mechanisms governing HIF-1α protein stabilization and function have been well studied, those governing HIF1A gene expression are not fully understood. However, recent studies have suggested that methylation of a HIF-1 binding site in the HIF1A promoter prevents its autoregulation. Here we report that the POZ-ZF transcription factor Kaiso modulates HIF1A gene expression by binding to the methylated HIF1A promoter in a region proximal to the autoregulatory HIF-1 binding site. Interestingly, Kaiso's regulation of HIF1A occurs primarily during hypoxia, which is consistent with the finding that Kaiso protein levels peak after 4 h of hypoxic incubation and return to normoxic levels after 24 h. Our data thus support a role for Kaiso in fine-tuning HIF1A gene expression after extended periods of hypoxia.

The reliability and accuracy of an electromagnetic motion analysis system when used conjointly with an accelerometer

The effect of an accelerometer driven electronic postural monitor (Spineangel®) placed within the electromagnetic measurement field of the Polhemus Fastrak™ is unknown. This study assessed the reliability and accuracy of Fastrak™ linear and angular measurements, when the Spineangel® was placed close to the sensor(s) and transmitter. Bland Altman plots and intraclass correlation coefficient (2,1) were used to determine protocol reproducibility and measurement consistency. Excellent reliability was found for linear and angular measurements (0.96, 95% CI: 0.90-0.99; and 1.00, 95% CI: 1.00-1.00, respectively) with the inclusion of Spineangel®; similar results were found, without the inclusion of Spineangel®, for linear and angular measurements, (0.96, 95% CI: 0.89-0.99; and 1.00, 95% CI: 1.00-1.00, respectively). The greatest linear discrepancies between the two test conditions were found to be less than 3.5 mm, while the greatest angular discrepancies were below 3.5°. As the effect on accuracy was minimal, these findings support the conjoint use of the Fastrak™ during validation studies of the Spineangel® device. STATEMENT OF RELEVANCE: Although previous studies have used the Fastrak™ as the gold standard measurement system, the influence of an accelerometer driven postural monitor on accuracy has not been reported. The strength of the present study has been to determine the effect of accelerometer placement within the electromagnetic field on the reliability and accuracy of the Fastrak™.

Can postural modification reduce kinetic and kinematic loading during the bowing postures of Islamic prayer?

As stooped postures are known to increase kinematic and kinetic loading on the lumbar spine they can be problematic for people with low back pain and postural task modification is often recommended. For the Muslim with low back pain, the bowing postures during prayer can aggravate low back symptoms. The aims of this study were to describe lumbo-sacral and pelvic tilt kinematics and lumbo-sacral kinetics during the standard bowing postures of Islam and to compare these to kinematic and kinetic data gathered during a clinically recommended modified bowing posture. The study was a repeated measures within subject cross-over design with 33 healthy male Muslim participants. 3-D motion analysis data were gathered to calculate body joint angles during the two bowing postures. A 3-D biomechanical model was then used to calculate spinal loads. Paired t-test analyses showed that the use of the modified posture resulted in significantly less pelvic tilt range of motion and anterior shear force and compressive force L5/S1, at stages 1 and 5 of bowing. Although this study was conducted with healthy young Muslim males, the use of this modified bent knee posture is recommended for all Muslims with low back pain. Clinical trials are being considered to determine the clinical utility of this postural manoeuvre as an intervention. STATEMENT OF RELEVANCE: The presence of low back pain may hinder a Muslim's ability to use the traditional Islamic bowing posture. Muslims who have low back pain may benefit from adopting a modification to the traditional bowing posture, which has been found to reduce the loads and postural demands on the lower back.

The relationship between physical activity and low back pain outcomes: a systematic review of observational studies

Although clinical guidelines advocate exercise and activity in the management of non-specific low back pain (NSLBP), the link between levels of physical activity and outcomes is unclear. This systematic review investigated the relationships between free living activity levels after onset of low back pain (LBP) and measures of pain, and disability in patients with NSLBP. Cohort and cross-sectional studies were located using OVID, CINAHL, Medline, AMED, Embase, Biomed, PubMed-National Library of Medicine, Proquest and Cochrane Databases, and hand searches of reference lists. Studies were included if a statistical relationship was investigated between measures of free living physical activity (PA) in subjects with LBP and LBP outcome measures. Twelve studies (seven cohort and five cross-sectional) were included. One prospective study reported a statistically significant relationship between increased leisure time activity and improved LBP outcomes, and one cross-sectional study found that lower levels of sporting activity were associated with higher levels of pain and disability. All other studies (n = 10) found no relationship between measures of activity levels and either pain or disability. Heterogeneity of study designs, particularly in terms of activity measurement, made comparisons between studies difficult. These data suggest that the activity levels of patients with NSLBP are neither associated with, nor predictive of, disability or pain levels. Validated activity measurement in prospective research is required to better evaluate the relationships between PA and LBP.

The effectiveness of walking as an intervention for low back pain: a systematic review

As current low back pain (LBP) guidelines do not specifically advocate walking as an intervention, this review has explored for the effectiveness of walking in managing acute and chronic LBP. CINAHL, Medline, AMED, EMBASE, PubMed, Cochrane and Scopus databases, as well as a hand search of reference lists of retrieved articles, were searched. The search was restricted to studies in the English language. Studies were included when walking was identified as an intervention. Four studies met inclusion criteria, and were assessed with a quality checklist. Three lower ranked studies reported a reduction in LBP from a walking intervention, while the highest ranked study observed no effect. Heterogeneity of study design made it difficult to draw comparisons between studies. There is only low-moderate evidence for walking as an effective intervention strategy for LBP. Further investigation is required to investigate the strength of effect for walking as a primary intervention in the management of acute and chronic LBP.

Can accelerometry be used to discriminate levels of activity?

The aims of this study were to investigate the associations between an activity logbook and the RT3 accelerometer and to assess whether the RT3 can discriminate activity levels in healthy adults. Ten participants completed two trials wearing an RT3 accelerometer over a 4-6 h period and completed a detailed activity log. Results showed a poor correlation between the RT3 in moderate activities (r = 0.22) in comparison to low (r = 0.52) and hard (r = 0.70) from the logbook. A significant difference was found in average RT3 vector magnitude (VM) counts/min in each activity level (p < 0.0001). Discriminant analysis demonstrated that an RT3VM counts/min value of approximately 500 was found to have high sensitivity (88%), and specificity (88%) for discriminating between low and moderate activity levels from the logbook. This study found that accelerometry has the potential to discriminate activity levels in free living. This study is the first to investigate whether tri-axial accelerometry can discriminate different levels of free-living activity recorded in an activity logbook. The RT3 accelerometer can discriminate between low and moderate physical activities and offers a methodology that may be applicable to future research in occupational settings.

Variability of essential oils of Satureja montana L. and Satureja kitaibelii wierzb. ex Heuff. from the central part of the balkan peninsula

The results of the essential oil composition confirm that there are differences between populations within the same subspecies (Satureja montana ssp. montana, between the subspecies (Satureja montana ssp. montana and Satureja montana ssp. pisidica) and the species (Satureja montana and S. kitabelii). The essential oil composition of S. montana ssp. montana is more related to the Satureja montana ssp. pisidica than S. kitaibelii which separates as a whole species.